Qsymia for Weight Loss

Qsymia is one capsule holding two very different medicines. Phentermine has been prescribed for short-term appetite suppression since the 1950s and works through catecholamine release in the hypothalamus. Topiramate arrived as an epilepsy drug, and weight loss showed up as a side effect nobody designed for. Pairing them lets each sit at a lower dose than it would need alone. The FDA label is candid that the precise weight-related mechanism of either component is not fully known, which is unusual honesty for a marketed combination. The topiramate here is extended-release, so the whole dose goes down once in the morning. Evening dosing is specifically discouraged because insomnia is a recognized effect. The four strengths are fixed ratios rather than separate dials, so titration means moving up a tier rather than adjusting one half. The combination was approved under application 022580 in 2012, and the topiramate dose even at the top tier stays well under what epilepsy treatment typically uses.

EQUIP enrolled adults with a BMI of 35 or higher and ran 56 weeks. Average loss reached 10.9% at 15/92 mg and 5.1% at 3.75/23 mg, against 1.6% on placebo. CONQUER recruited 2,487 adults with a lower BMI floor plus weight-related conditions, and reported 7.8% at 7.5/46 mg and 9.8% at 15/92 mg against 1.2% on placebo. Those two trials, both funded by the manufacturer, are the whole approval case.

Responder rates matter more than averages when you are deciding whether to start. In CONQUER, 62% at the mid dose and 70% at the top dose lost at least 5% of starting weight, against 21% on placebo, and 37% and 48% respectively passed 10%. Averages hide the split: a large share of that gain sits with strong responders, while others move very little. That is exactly why the label builds stopping rules around your own 12-week response rather than the trial mean.

SEQUEL extended CONQUER by another 52 weeks. At week 108, loss was 9.3% at 7.5/46 mg and 10.5% at 15/92 mg against 1.8% on placebo, and incident type 2 diabetes fell. Read it with a caveat the headline rarely carries: 676 of 866 eligible adults at selected sites elected to continue, so the two-year figure describes a self-selected group who had already tolerated a year of treatment. It shows durability. It is not a fresh trial.

The current indication covers adults and those aged 12 and older with obesity, plus adults with overweight who also carry a weight-related condition such as high blood pressure, type 2 diabetes or dyslipidemia. The adolescent extension arrived in 2022. Both indications are explicitly adjuncts to a reduced-calorie diet and more physical activity, which is not boilerplate: every efficacy figure above came from trials that provided lifestyle support to every arm, placebo included.

The adolescent evidence is thinner than the adult evidence and comes with signals worth weighing. In the 56-week study of 223 teenagers, height velocity ran about 1.3 to 1.4 cm per year lower than placebo, and bone mineral density Z-scores dropped by half a standard deviation or more in 30% of those at the top dose against none on placebo. A clinician weighing this for a 14-year-old is balancing a real metabolic benefit against growth measures that need tracking, and that judgment is not one a website can make for you.

A 2026 network meta-analysis pooling 262 trials and 99,791 enrolled adults ranked 19 weight drugs against lifestyle alone at one year. Phentermine with topiramate landed at 8.1%, behind tirzepatide at 14.9%, oral semaglutide at 10.9% and injected semaglutide at 9.8%. A separate 2026 living review for the American College of Physicians reached the same ordering. On raw weight loss this is not the front of the field, and pretending otherwise helps nobody.

The honest case for it is different. It is a capsule, it needs no refrigeration, and the generic versions cost a fraction of what a branded injectable does without insurance. Against that, the same 2026 analysis flagged this combination among the treatments with the highest discontinuation for adverse effects, and no trial has shown that it lowers cardiovascular risk or death, a claim injected semaglutide now has and this does not. Supply, cost, needle tolerance and what your insurance will actually cover tend to decide this more than the percentage gap does.

The schedule works like a decision tree. You take 3.75/23 mg each morning for 14 days, then 7.5/46 mg, which is the recommended maintenance dose for most. At 12 weeks on that dose, weight loss under 3% of starting weight is the trigger to either escalate or stop, and escalation means 11.25/69 mg for another 14 days before reaching 15/92 mg. Morning dosing is not arbitrary; evening doses raise the odds of insomnia.

The second checkpoint is the one that ends treatment. After 12 weeks at 15/92 mg, weight loss under 5% means the label directs discontinuation, because a further response is unlikely. Coming off the top dose is not a clean stop: topiramate withdrawal can provoke a seizure, so 15/92 mg is tapered by taking it every other day for at least a week. Kidney or liver impairment caps the dose at 7.5/46 mg, and severe impairment or dialysis rules it out entirely.

Topiramate crosses the placenta and raises the risk of cleft lip and cleft palate. Data from the North American Antiepileptic Drug Pregnancy Registry found oral clefts in 1.4% of infants exposed in the first trimester, against 0.11% with no exposure, a relative risk of 12.5. A UK register reported 3.2% against a 0.2% background. Major malformations excluding clefts ran 4.1% against 1.1%, and small-for-gestational-age births 19.7% against 5.4%.

The weight loss is not the defining fact about this medication. This risk is.

Everything procedural follows from it. A negative pregnancy test is required before you start and monthly while you continue, and effective contraception is required throughout. One detail is widely garbled online: topiramate at these doses lowers ethinyl estradiol exposure by about 16% and raises norethindrone by 22%, and the label states this is not anticipated to increase the chance of pregnancy. Irregular bleeding or spotting can happen, and the label specifically advises not to stop a combined oral contraceptive because of it.

Because of the teratogenic risk, the medication is only distributed through a restricted program under a REMS. A point often stated backwards: the REMS certifies pharmacies. Prescribers are not the gate. The practical effect is that your prescription has to reach a certified pharmacy rather than any counter you walk up to. If pregnancy occurs during treatment, the label directs stopping immediately and reporting the exposure to the pregnancy registry.

Two effects account for most of the quitting, and both get described too vaguely elsewhere. Pins and needles in the hands, feet or face affected 14% at 7.5/46 mg and 20% at 15/92 mg against 2% on placebo. Cognitive effects, meaning trouble holding attention, retrieving words or remembering, ran 5.0% and 7.6% against 1.5%. Dry mouth, constipation and altered taste sit in the same tier. Roughly 1% stopped over the tingling alone, so the numbers reporting an effect are far higher than the numbers it defeats.

Topiramate inhibits carbonic anhydrase, which pushes bicarbonate down and can produce metabolic acidosis. Persistent bicarbonate under 21 mEq/L appeared in 6.4% at 7.5/46 mg and 12.8% at 15/92 mg, usually peaking within four weeks of a dose step and correcting on its own by week 56 in most cases. That is why blood chemistry including bicarbonate, creatinine and potassium is checked before starting and periodically after. Low potassium appeared in around 5% at the top dose, and 88% of those were also taking a non-potassium-sparing diuretic. Kidney stones reached 1.2%.

Two more warrant naming. Acute angle-closure glaucoma is a topiramate class effect and glaucoma is listed as a contraindication, so sudden eye pain or blurred vision is an urgent call rather than a wait-and-see. Mood and sleep disturbance of any kind reached 21% at the top dose against 10% on placebo, with insomnia, anxiety and low mood all rising with dose, and antiepileptic drugs as a class carry a suicidality warning. Average heart rate rose about 3.6 beats per minute. Report new symptoms rather than pushing through them.

The hard stops come first. MAO inhibitors are contraindicated, including within 14 days of stopping one, as are pregnancy, glaucoma, hyperthyroidism and known reaction to sympathomimetic amines. Diuretics that are not potassium-sparing deepen the potassium fall this combination already causes, and other carbonic anhydrase inhibitors stack on the acidosis and stone risk. Alcohol and central nervous system depressants amplify the cognitive fog. Anyone taking an antidiabetic medication also needs glucose watched, since weight loss can push doses that were correct last month into hypoglycemia this month.

Switching is the more common question in practice, usually to or from a GLP-1 when supply, insurance or tolerance changes. There is no published trial of running the two together, and the label does not describe combination use, so that decision sits entirely with a prescriber who knows your history. Going the other way, the taper rule still applies: coming off 15/92 mg needs the every-other-day week regardless of what is replacing it. Which of those applies to you is a prescriber's call.

Real numbers beat vague ranges here. Under the CMS National Average Drug Acquisition Cost benchmark published on 2 September 2026, generic phentermine and topiramate extended-release capsules ran $3.23, $3.29, $3.14 and $3.18 per capsule across the four strengths, so roughly $94 to $99 for 30 days. That figure is what pharmacies pay to buy the product. It is not what any counter or platform charges you, and cash prices, dispensing fees and margins sit on top of it.

Set that against the separate components on the same benchmark: generic phentermine 37.5 mg tablets at about $0.07 and topiramate 50 mg tablets at about $0.04, roughly eleven cents a day for the pair against more than three dollars. The gap is around thirtyfold, and it is worth understanding what the premium buys: the extended-release topiramate formulation, the fixed once-daily ratio, and an approval that covers weight management. Prescribing the two generics separately for weight is a different and unapproved use, and whether that trade makes sense is a conversation with a prescriber, never a self-service decision.

The label is explicit that phentermine is a Schedule IV controlled substance while topiramate is not, and that single fact shapes the logistics. Controlled-substance prescriptions cannot be refilled indefinitely, state rules vary on remote prescribing, and some telehealth services simply do not handle this class at all. Add the REMS requirement that a certified pharmacy dispenses it, and you have two filters most weight-loss services do not advertise clearly. Ask about both before you pay for a consultation. None of this is medical advice, and only a prescriber who knows your history can decide whether this medication suits you.

When comparing services, the criteria that matter are concrete. Does the clinician prescribe controlled substances in your state, can they route the prescription to a certified pharmacy, will they order the baseline and follow-up blood chemistry the label calls for, and is monthly pregnancy testing built into the plan where it applies.

A service that cannot answer all four is not set up for this medication.